PHARMACOKINETIC INTERACTION BETWEEN IVACAFTOR AND LUMACAFTOR IN CYSTIC FIBROSIS PATIENTS

被引：0
|
作者：
Hanafin, P. [2 ]
Rao, G. [2 ]
Schneider-Futschik, E. [1 ]
机构：
[1] Univ Melbourne, Melbourne, Vic, Australia
[2] UNC Eshelman Sch Pharm, Chapel Hill, NC USA
来源：
RESPIROLOGY | 2020年 / 25卷
基金：
英国医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
TO 070
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [41] Multi-Omics Profiling of Lumacaftor/Ivacaftor Response in Cystic Fibrosis
    Kopp, B. T.
    Fitch, J. R.
    Zhang, S.
    Shrestha, C. L.
    Woodley, F. W.
    Hayes, D.
    White, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [42] Combination Therapy with Lumacaftor-Ivacaftor in Cystic Fibrosis Keeping It Real
    Sala, Marc A.
    Jain, Manu
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201 (02) : 133 - 134
  • [43] Characterization Of Ivacaftor And Lumacaftor Using Biomap® Profiling - Implications For Cystic Fibrosis
    Velichko, S.
    Berg, E.
    Folias, A.
    Bassoni, D.
    O'Mahony, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [44] T-cell-mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis
    Semic-Jusufagic, Aida
    Ogese, Monday O.
    Edwards, Christopher
    Wilkinson, Mark
    Nissenbaum, Claire
    Lee, Tim
    Pirmohamed, Munir
    Naisbitt, Dean J.
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2022, 33 (06)
  • [45] Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR
    Rowe, Steven M.
    McColley, Susanna A.
    Rietschel, Ernst
    Li, Xiaolei
    Bell, Scott C.
    Konstan, Michael W.
    Marigowda, Gautham
    Waltz, David
    Boyle, Michael P.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2017, 14 (02) : 213 - 219
  • [46] Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function
    Burgel, Pierre-Regis
    Durieu, Isabelle
    Chiron, Raphael
    Mely, Laurent
    Prevotat, Anne
    Murris-Espin, Marlene
    Porzio, Michele
    Abely, Michel
    Reix, Philippe
    Marguet, Christophe
    Macey, Julie
    Sermet-Gaudelus, Isabelle
    Corvol, Harriet
    Bui, Stephanie
    Biouhee, Tiphaine
    Hubert, Dominique
    Munck, Anne
    Lemonnier, Lydie
    Dehillotte, Clemence
    Da Silva, Jennifer
    Paillasseur, Jean-Louis
    Martin, Clemence
    JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (02) : 220 - 227
  • [47] LUMACAFTOR/IVACAFTOR COMBINATION FOR CYSTIC FIBROSIS PATIENTS HOMOZYGOUS FOR PHE508DEL-CFTR
    Zhang, W.
    Zhang, X.
    Zhang, Y. H.
    Stokes, D. C.
    Naren, A. P.
    DRUGS OF TODAY, 2016, 52 (04) : 229 - 237
  • [48] Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
    Wainwright, C. E.
    Elborn, J. S.
    Ramsey, B. W.
    Marigowda, G.
    Huang, X.
    Cipolli, M.
    Colombo, C.
    Davies, J. C.
    De Boeck, K.
    Flume, P. A.
    Konstan, M. W.
    McColley, S. A.
    Mccoy, K.
    McKone, E. F.
    Munck, A.
    Ratjen, F.
    Rowe, S. M.
    Waltz, D.
    Boyle, M. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03): : 220 - 231
  • [49] Changes in Glucose Breath Test in Cystic Fibrosis Patients Treated With 1 Month of Lumacaftor/Ivacaftor
    Gabel, Megan E.
    Wang, Hongyue
    Gelfond, Daniel
    Roach, Christine
    Rowe, Steven M.
    Clancy, John P.
    Sagel, Scott D.
    Borowitz, Drucy
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2022, 75 (01): : 42 - 47
  • [50] Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor
    Li, Angel
    Vigers, Tim
    Pyle, Laura
    Zemanick, Edith
    Nadeau, Kristen
    Sagel, Scott D.
    Chan, Christine L.
    JOURNAL OF CYSTIC FIBROSIS, 2019, 18 (01) : 144 - 149
12345